39
[1] J.A. Coderre et al., Derivations of relative biological effectiveness for the high-let radiations produced during boron neutron capture
irradiations of the 9l rat gliosarcoma in vitro and in vivo, Int. J. Radiat. Oncol. Biol. Phys. 27(5) (1993), 1121–1129. doi:10.1016/03603016(93)90533-2.
[2] J.A. Coderre et al., Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: Boron concentration correlates with
tumor cellularity, Radiat. Res. 149(2) (1998), 163–170, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/9457896. doi:10.2307/
3579926.
[3] J.A. Coderre, G.M. Morris, P.L. Micca, C.D. Fisher and G.A. Ross, Comparative assessment of single-dose and fractionated boron neutron
capture therapy, Radiat. Res. 144(3) (1995), 310–317, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/7494875. doi:10.2307/
3578951.
[4] H. Fukuda et al., Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal
skin and tumor, Australas. Phys. Eng. Sci. Med. 26(3) (2003), 97–103. doi:10.1007/BF03178777.
38
37
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
[research-article]
10
11
12
13
14
15
16
17
18
19
[5] N. Hu et al., Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an
independent Monte Carlo dose calculation system, Radiat. Oncol. 16(1) (2021), 1–13. doi:10.1186/s13014-021-01968-2.
[6] International Atomic Energy Agency, Current Status of Neutron Capture Therapy, no. 1223. Vienna: IAEA-TECDOC-1223, 2001.
[7] S. Jednoróg, M. Scholz, M. Paduch, B. Bienkowska and A. Szydłowski, Preliminary determination of angular distribution of neutrons
emitted from PF-1000 facility by indium activation, Nukleonika 57(4) (2012), 563–568.
[8] S. Kawabata et al., Accelerator-based BNCT for patients with recurrent glioblastoma: A multicenter phase II study, Neuro-Oncology Adv.
3(1) (2021), 1–9. doi:10.1093/noajnl/vdab067.
[9] Y. Kiyanagi, Y. Sakurai, H. Kumada and H. Tanaka, Status of accelerator-based BNCT projects worldwide, AIP Conf. Proc. 2160 (2019).
doi:10.1063/1.5127704.
[10] A.J. Kreiner et al., Present status of accelerator-based BNCT, Reports Pract. Oncol. Radiother. 21(2) (2016), 95–101. doi:10.1016/j.rpor.
2014.11.004.
[11] T. Mitsumoto et al., Cyclotron-based neutron source for BNCT, AIP Conf. Proc. 1525 (2013), 319–322. doi:10.1063/1.4802341.
[12] T.L. Nichols, L.F. Miller and G.W. Kabalka, The microdosimetry of boron neutron capture therapy in a randomised ellipsoidal cell
geometry, Radiat. Prot. Dosimetry 116(1–4) (2005), 466–469. doi:10.1093/rpd/nci248.
[13] Y. Sakurai and T. Kobayashi, Characteristics of the KUR heavy water neutron irradiation facility as a neutron irradiation field with variable
energy spectra, Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 453(3) (2000), 569–596. doi:10.
1016/S0168-9002(00)00465-4.
[14] T. Sato et al., Features of particle and heavy ion transport code system (PHITS) version 3.02, J. Nucl. Sci. Technol. 55(6) (2018), 684–690.
doi:10.1080/00223131.2017.1419890.
[15] H. Tanaka et al., Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS), Appl. Radiat.
Isot. 69(12) (2011), 1642–1645. doi:10.1016/j.apradiso.2011.03.020.
[16] J.C. Yanch, X.-L. Zhou and G.L. Brownell, A Monte Carlo investigation of the dosimetric properties of monoenergetic neutron beams for
neutron capture therapy, Radiat. Res. 126(1) (1991), 1–20. doi:10.2307/3578165.
N. Hu et al. / Accelerator based epithermal neutron source for clinical boron neutron capture therapy
PR
p. 8/8
20
10
11
12
13
14
15
16
17
18
19
20
21
22
22
21
23
TE
24
25
26
EC
27
28
29
30
31
32
33
34
35
36
40
41
42
43
44
39
38
37
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
45
46
46
47
47
48
48
49
49
50
50
...
論文の公開元へ
